News Release

China Pharma News correction

Date: 2000/03/17

China Pharma News has requested that International Wex Technologies Inc. ( the "company") change two words on our prior news release regarding themselves from "due diligence" to what they believe to be more accurate. In their words, "The China Pharma News story was a journalistic investigative report conducted by China Concept Consulting on a product in response to requests received for such coverage. It did not, in scope or depth, constitute a due diligence report by China Concept Consulting on Tetrodin." They continue coverage on Tetrodin (HT).

Tetrodin (HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin (HT) as a potent analgesic.

For additional information on Tetrodin (HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary